TrivarX Ltd. engages in clinical research, product development, and early-stage commercialization of mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción MDBIF?
El precio actual de MDBIF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de TrivarX Ltd?
TrivarX Ltd pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de TrivarX Ltd?
La capitalización bursátil actual de TrivarX Ltd es $0
